SAO PAULO, March 23, 2016 /PRNewswire/ -- Profarma Distribuidora de Produtos Farmaceuticos S.A. (BM&FBOVESPA: PFRM3) is pleased to invite you to participate in our conference call about the 4Q15 and FY2015 results.
The earnings will be released today, March 23, 2016, after BM&FBOVESPA's trading session.
Save the date: March 24, 2016
Access Code: Profarma
English (simultaneous translation):
01:00 PM (EST)
02:00 PM (Brasilia time)
(1-888) 700-0802 (toll free dos EUA)
(1-786) 924-6977 (Other country)
(55-11) 2820-4001 and (55-11) 3193-1001 (Brazil)
The live webcast will be available at https://ri.profarma.com.br/en
CEO (Chief Executive Officer)
CFO (Chief Financial Officer) and Investor Relations Officer
Profarma Distribuidora de Produtos Farmaceuticos S.A. has been active for 55 years in distributing pharmaceutical, personal care and cosmetic products in the most populous Brazilian states. Since 2013, it has also been one of Latin America's largest mixed distributors–and Brazil's largest–after acquiring the drugstore chain Drogasmil/Farmalife and Tamoio. With 11 distribution centers, Profarma markets approximately 18 million units per month and serves about 33 thousand points of sale. In the pharmaceutical retail market, it has become Brazil's 10th largest drugstore chain, with 129 stores in Rio de Janeiro State. Covering a geographic area comprising 96% of the consumer market for pharmaceutical products in Brazil, Profarma boasts a specialized and committed team that constantly seeks to make it the largest and most profitable pharmaceutical wholesaler in Brazil by achieving consistent and sustainable results, keeping operating costs down, strengthening its competitive advantages and maximizing value for its stockholders. The Profarma Specialty Group is a joint venture between Profarma and AmerisourceBergen, each with a 50% stake. AmerisourceBergen is one of the largest pharmaceutical distribution company in the world, and caters for both health services providers and pharmaceutical and biotechnology companies. The Joint Venture aims at concentrate all businesses related to hospitals products, vaccines, dermatologic products, as well as specialties products, through the companies Profarma Specialty e Arpmed.
+55 21 4009-0270
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/follow-our-conference-call-4q15--profarma-300239974.html
SOURCE Profarma Distribuidora de Produtos Farmaceuticos S.A.